Autres domaines


SARS-CoV-2 microbiome dysbiosis linked disorders and possible probiotics role - 19/12/20

Doi : 10.1016/j.biopha.2020.110947 
Ahmad Ud Din a, 1, Maryam Mazhar b, 1, Muhammed Waseem c, Waqar Ahmad d, a, Asma Bibi e, Adil Hassan f, Niaz Ali g, Wang Gang a, Gao Qian a, Razi Ullah f, Tariq Shah h, Mehraj Ullah i, Israr Khan j, Muhammad Farrukh Nisar k, Jianbo Wu a,
a Drug Discovery Research Center, Southwest Medical University, Luzhou, 646000, Sichuan, China 
b Research Center of Integrated Traditional Chinese and Western Medicine, Affiliated Traditional Medicine Hospital, Southwest Medical University, Luzhou, China 
c State Key Laboratory for Conservation and Utilization of Subtropical Agro-Bioresources, College of Horticulture, South China Agricultural University, Guangzhou, 510642, China 
d College of Marine Life Sciences and Institute of Evolution and Marine Biodiversity, Ocean University of China, Qingdao, 266003, China 
e Institute of Zoonosis Anhui Medical University, Hefei Anhui, 230032, China 
f Key Laboratory for Bio-rheological Science and Technology of Ministry of Education, State and Local Joint Engineering Laboratory for Vascular Implants Bioengineering College of Chongqing University, Chongqing, 400030, China 
g State Key Laboratory for Conservation and Utilization of Subtropical Agro-bio-resources, College of Life Science and Technology, Guangxi University, 100 Daxue Road, Nanning, 530004, Guangxi, China 
h State Key Laboratory of Grassland Agro-Ecosystem, School of Life Sciences, Lanzhou University, Lanzhou, 730000, China 
i Department of Biotechnology School of Fermentation Engineering Tianjin University of Science and Technology China, China 
j School of Life Sciences, Lanzhou University, China 
k Department of Physiology and Biochemistry, Cholistan University of Veterinary and Animal Sciences (CUVAS), Bahawalpur, 63100, Pakistan 

Corresponding author at: Drug Discovery Research Center, Southwest Medical University, Luzhou, 646000, China.Drug Discovery Research CenterSouthwest Medical UniversityLuzhou646000China

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
Artículo gratuito.

Conéctese para beneficiarse!

Graphical abstract

El texto completo de este artículo está disponible en PDF.


Gut microbial diversity dysbiosis leads to increased death in COVID-19.
High death tool in COVID-19 is due to microbiome disturbance in co-morbid patients.
More deaths in ICU Individual seems to be because of microbiome dysbiosis.
Probiotics can be a Supplementary Therapy to decrease death tool in COVID-19.

El texto completo de este artículo está disponible en PDF.


In December 2019, a pneumonia outbreak of unknown etiology was reported which caused panic in Wuhan city of central China, which was later identified as Coronavirus disease (COVID-19) caused by a novel coronavirus, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) by the Chinese Centre for Disease Control and Prevention (CDC) and WHO. To date, the SARS-CoV-2 spread has already become a global pandemic with a considerable death toll. The associated symptoms of the COVID-19 infection varied with increased inflammation as an everyday pathological basis. Among various other symptoms such as fever, cough, lethargy, gastrointestinal (GI) symptoms included diarrhea and IBD with colitis, have been reported. Currently, there is no sole cure for COVID-19, and researchers are actively engaged to search out appropriate treatment and develop a vaccine for its prevention. Antiviral for controlling viral load and corticosteroid therapy for reducing inflammation seems to be inadequate to control the fatality rate. Based on the available related literature, which documented GI symptoms with diarrhea, inflammatory bowel diseases (IBD) with colitis, and increased deaths in the intensive care unit (ICU), conclude that dysbiosis occurs during SARS−COV-2 infection as the gut-lung axis cannot be ignored. As probiotics play a therapeutic role for GI, IBD, colitis, and even in viral infection. So, we assume that the inclusion of studies to investigate gut microbiome and subsequent therapies such as probiotics might help decrease the inflammatory response of viral pathogenesis and respiratory symptoms by strengthening the host immune system, amelioration of gut microbiome, and improvement of gut barrier function.

El texto completo de este artículo está disponible en PDF.

Keywords : COVID-19, IBD, Colitis, ICU, Gut microbiome, Probiotics


© 2020  The Author(s). Publicado por Elsevier Masson SAS. Todos los derechos reservados.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir

    Exportación citas

  • Fichero

  • Contenido

Vol 133

Artículo 110947- janvier 2021 Regresar al número
Artículo precedente Artículo precedente
  • The involvement of noncanonical Wnt signaling in cancers
  • Yongfeng Chen, Zhengxi Chen, Yin Tang, Qian Xiao
| Artículo siguiente Artículo siguiente
  • Therapeutic mechanisms of traditional Chinese medicine to improve metabolic diseases via the gut microbiota
  • Hai-Yu Zhang, Jia-Xing Tian, Feng-Mei Lian, Min Li, Wen-Ke Liu, Zhong Zhen, Jiang-Quan Liao, Xiao-Lin Tong

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.

Mi cuenta

Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.